SOPHiA GENETICS Releases Preliminary Financial Results and Transitions Leadership for Future Growth SOPHiA GENETICS unveils strong preliminary financial performance for Q4 2025 and outlines guidance for 2026, including leadership transitions.

SOPHiA GENETICS Releases Preliminary Financial Results and Transitions Leadership for Future Growth #Boston #Switzerland #SOPHiA_GENETICS #Jurgi_Camblong #Ross_Muken

SOPHiA GENETICS Reports Positive Financial Progress for 2025 and Plans for 2026 SOPHiA GENETICS shares impressive preliminary results for Q4 2025 and full-year insights, projecting significant revenue growth for 2026 along with new leadership.

SOPHiA GENETICS Reports Positive Financial Progress for 2025 and Plans for 2026 #USA #Boston #SOPHiA_GENETICS #Ross_Muken #AI-driven_medicine

SOPHiA GENETICS Reveals Impressive Q4 Results and 2026 Forecast SOPHiA GENETICS announces strong preliminary Q4 results for 2025 and ambitious forecasts for 2026 while promoting new leadership.

SOPHiA GENETICS Reveals Impressive Q4 Results and 2026 Forecast #USA #Boston #SOPHiA_GENETICS #Jurgi_Camblong #Ross_Muken